277 related articles for article (PubMed ID: 25189027)
1. [Erdheim-Chester disease].
Mazor RD; Shoenfeld Y
Harefuah; 2014 Jul; 153(7):389-91, 434, 433. PubMed ID: 25189027
[TBL] [Abstract][Full Text] [Related]
2. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
[TBL] [Abstract][Full Text] [Related]
3. Erdheim-Chester disease.
Campochiaro C; Tomelleri A; Cavalli G; Berti A; Dagna L
Eur J Intern Med; 2015 May; 26(4):223-9. PubMed ID: 25865950
[TBL] [Abstract][Full Text] [Related]
4. Erdheim-Chester disease.
Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
Rheum Dis Clin North Am; 2013 May; 39(2):299-311. PubMed ID: 23597965
[TBL] [Abstract][Full Text] [Related]
5. Erdheim-Chester disease.
Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
Curr Rheumatol Rep; 2014 Apr; 16(4):412. PubMed ID: 24532298
[TBL] [Abstract][Full Text] [Related]
6. A cytologic diagnosis of BRAF
Chasseur P; Kyriakopoulou M; Vokaer B; Beukinga I; Casado Arroyo R; Cogan E; Couturier B
Acta Clin Belg; 2017 Oct; 72(5):369-371. PubMed ID: 28222655
[TBL] [Abstract][Full Text] [Related]
7. Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.
Mazor RD; Manevich-Mazor M; Kesler A; Aizenstein O; Eshed I; Jaffe R; Pessach Y; Goldberg I; Sprecher E; Yaish I; Gural A; Ganzel C; Shoenfeld Y
BMC Med; 2014 Dec; 12():221. PubMed ID: 25434739
[TBL] [Abstract][Full Text] [Related]
8. A case of Erdheim-Chester disease with spinal cord compression and sphenoid sinus involvement.
Bunaux K; Sevestre H; Emile JF; Capel C; Chenin L; Peltier J
Neurochirurgie; 2018 Dec; 64(6):439-441. PubMed ID: 30274919
[TBL] [Abstract][Full Text] [Related]
9. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
[TBL] [Abstract][Full Text] [Related]
10. Erdheim-Chester Disease: a comprehensive review of the literature.
Mazor RD; Manevich-Mazor M; Shoenfeld Y
Orphanet J Rare Dis; 2013 Sep; 8():137. PubMed ID: 24011030
[TBL] [Abstract][Full Text] [Related]
11. Low-dose vemurafenib monotherapy in
Ruan GJ; Hazim A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
Leuk Lymphoma; 2020 Nov; 61(11):2733-2737. PubMed ID: 32608295
[No Abstract] [Full Text] [Related]
12. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report.
Tzoulis C; Schwarzlmüller T; Gjerde IO; Søfteland E; Neckelmann G; Biermann M; Haroche J; Straume O; Vintermyr OK
BMC Res Notes; 2015 Apr; 8():171. PubMed ID: 25926131
[TBL] [Abstract][Full Text] [Related]
13. Hypoalphalipoproteinemia and BRAF
Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
[TBL] [Abstract][Full Text] [Related]
14. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
[TBL] [Abstract][Full Text] [Related]
15. Biological and therapeutic implications of the BRAF pathway in histiocytic disorders.
Arceci RJ
Am Soc Clin Oncol Educ Book; 2014; ():e441-5. PubMed ID: 24857137
[TBL] [Abstract][Full Text] [Related]
16. Dramatic response to encorafenib in a patient with Erdheim-Chester disease harboring the BRAF
Wada F; Hiramoto N; Yamashita D; Hara S; Furukawa Y; Ishii J; Nagata K; Nannya Y; Ogawa S; Ishikawa T
Am J Hematol; 2021 Aug; 96(8):E295-E298. PubMed ID: 33971044
[No Abstract] [Full Text] [Related]
17. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
[TBL] [Abstract][Full Text] [Related]
18. Erdheim-Chester disease involving the breast--a rare but important differential diagnosis.
Guo S; Yan Q; Rohr J; Wang Y; Fan L; Wang Z
Hum Pathol; 2015 Jan; 46(1):159-64. PubMed ID: 25454479
[TBL] [Abstract][Full Text] [Related]
19. Does the BRAF(V600E) mutation herald a new treatment era for Erdheim-Chester disease? A case-based review of a rare and difficult to diagnose disorder.
Bosco J; Allende A; Varikatt W; Lee R; Stewart GJ
Intern Med J; 2015 Mar; 45(3):348-51. PubMed ID: 25735579
[TBL] [Abstract][Full Text] [Related]
20. Erdheim Chester disease with appendicular skeletal, renal and pleural involvement responding to Zelboraf (BRAF inhibitor) treatment: case report.
Borys D; Nystrom L; Song A; Lomasney LM
Skeletal Radiol; 2016 Oct; 45(10):1397-402. PubMed ID: 27423231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]